Celltrion Unveils First Quadruple-Action Obesity Drug Candidate, Outperforming Retatrutide in Animal Study
Celltrion is accelerating the development of what it says is the world’s first quadruple agonist for obesity, designed to address the limitations of existing treatments. The company has reported preclinical findings suggesting that the next-generation drug candidate could offer benefits beyond weigh
Celltrion has unveiled its first quadruple-action obesity drug candidate, CT-G32/SCO-940, which outperformed the triple agonist retatrutide in preclinical animal studies. The company showcased the potential of this novel treatment at TIDES Europe 2026, highlighting its ability to simultaneously target four hormonal pathways: GLP-1, GIP, glucagon, and amylin.
In overweight animal models, CT-G32/SCO-940 resulted in greater weight loss compared to retatrutide while preserving more lean mass, including muscle and bone. Additionally, the drug candidate demonstrated the capacity to lower excessively high blood insulin levels, suggesting possible applications in metabolic conditions beyond obesity, such as hyperinsulinemia.
Following preclinical success, Celltrion plans to submit an Investigational New Drug (IND) application to the FDA by February 2027, with the goal of initiating patient dosing in the second quarter of the same year.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
